Interstitial Cystitis pipeline market research report includes an assessment of the disease epidemiology, leading marketed products, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Interstitial cystitis (IC). The report also analyzes the clinical and commercial landscapes of IC, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
What are the key MoA in the interstitial cystitis pipeline market?
The key MoA in the interstitial cystitis pipeline market are Ion Channel Blocker, Receptor Antagonist, Enzyme Inhibitor, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Activator. Ion Channel Blocker has the highest number of pipeline products.
Interstitial cystitis pipeline market, by MoA
For more MoA insights, download a free report sample
What are the key RoA in the interstitial cystitis pipeline market?
The key RoA in the interstitial cystitis pipeline market are injection, oral, topical, and suppository. Injection has the highest number of pipeline products.
For more RoA insights, download a free report sample
What are the key molecule type in the interstitial cystitis pipeline market?
The key molecule type in the interstitial cystitis pipeline market are small molecule, biologic, and oligonucleotide. Small molecule has the highest number of pipeline products.
For more molecule type insights, download a free report sample
What are the key sponsors in the interstitial cystitis pipeline market?
Some of the key sponsors in the interstitial cystitis pipeline market are Astellas Pharma Inc, Allergan Ltd, Cairo University, University of Louisville, Asan Medical Center, and Nara Medical University. Astellas has sponsored the most clinical trials in IC over the past 10 years.
To know more about sponsor, download a free report sample
Market report overview
|Key MoA||Ion Channel Blocker, Receptor Antagonist, Enzyme Inhibitor, Protein and Peptide Inhibitor, Biological Factor Inhibitor, and Enzyme Activator|
|Key RoA||Injection, Oral, Topical, and Suppository|
|Key molecule type||Small Molecule, Biologic, and Oligonucleotide|
|Key sponsors||Astellas Pharma Inc, Allergan Ltd, Cairo University, University of Louisville, Asan Medical Center, and Nara Medical University|
GlobalData’s Interstitial Cystitis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type and Route of Administration
- Product Profiles with Sales Forecast
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Interstitial Cystitis market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Interstitial Cystitis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1.2 Report Scope
1.3 List of Tables and Figures
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Overview by Molecule Type
4.5 Marketed Drugs Profiles and Sales Forecasts
5 Pipeline Drugs Assessment
5.1 Late-stage Pipeline Drugs
5.2 Overview by Development Stage
5.3 Overview by Mechanism of Action
5.4 Overview by Route of Administration
5.5 Overview by Molecule Type
5.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
5.7 Therapy Area and Indication-specific PTSR and LoA
6 Clinical Trials Assessment
6.1 Historical Overview
6.2 Overview by Phase
6.3 Overview by Status
6.4 Overview by Phase for Ongoing and Planned Trials
6.5 Trials with Virtual Components
6.6 Geographic Overview
6.7 Single-Country and Multinational Trials by Region
6.8 Top 20 Sponsors with Breakdown by Phase
6.9 Top 20 Sponsors with Breakdown by Status
6.10 Overview by Endpoint Status
6.11 Overview by Race and Ethnicity
6.12 Enrollment Data
6.13 Top 20 countries for Trial Sites
6.14 Top 20 Sites Globally
6.15 Feasibility Analysis – Geographic Overview
6.16 Feasibility Analysis – Benchmark Models
7 Deals Landscape
7.1 Mergers, Acquisitions, and Strategic Alliances by Region
7.2 Recent Mergers, Acquisitions, and Strategic Alliances
8 Commercial Assessment
8.1 Key Market Players
9 Future Market Catalysts
10.2 Methodology – PTSR and LoA Analysis
10.3 About the Authors
10.4 Contact Us